We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+15.01%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.52B
AUM Growth
+$204M
Cap. Flow
+$511M
Cap. Flow %
20.25%
Top 10 Hldgs %
77.93%
Holding
47
New
3
Increased
4
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
ESTC icon
Elastic
ESTC
+$430M
2
MRKR icon
Marker Therapeutics
MRKR
+$36.4M
3
TPST icon
Tempest Therapeutics
TPST
+$18.6M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$10.1M
5
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$7.04M

Top Sells

Rank Stock Value
1
AYTU icon
AYTU BioPharma
AYTU
+$6K

Sector Composition

Rank Sector Weight
1 Healthcare 79.53%
2 Technology 18.54%
3 Industrials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$774M 30.68%
10,420,555
– –
ESTC icon
2
Elastic
ESTC
$6.5B
$454M 18.01%
+6,353,498
New +$430M
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$7.4B
$132M 5.24%
4,912,306
– –
ALLK
4
DELISTED
Allakos
ALLK
$119M 4.7%
2,268,188
– –
RARX
5
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$112M 4.43%
6,138,797
+645,161
+12% +$10.1M
ADAP
6
DELISTED
Adaptimmune Therapeutics
ADAP
$91M 3.61%
15,832,611
– –
CBIO
7
Crescent Biopharma
CBIO
$595M
$86.1M 3.41%
90,890
– –
SENS icon
8
Senseonics Holdings Inc
SENS
$254M
$80M 3.17%
1,544,413
– –
CRSP icon
9
CRISPR Therapeutics
CRSP
$4.64B
$59.7M 2.37%
2,090,678
– –
OBSV
10
DELISTED
ObsEva SA Ordinary Shares
OBSV
$58.1M 2.3%
4,586,563
– –
LQDA icon
11
Liquidia Corp
LQDA
$7.66B
$53.8M 2.14%
2,486,062
– –
EPZM
12
DELISTED
Epizyme, Inc
EPZM
$42.4M 1.68%
6,877,518
+416,667
+6% +$3.18M
AVEO
13
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$33.4M 1.33%
2,089,604
+219,800
+12% +$4.84M
MRSN
14
DELISTED
Mersana Therapeutics
MRSN
$33.2M 1.32%
325,771
– –
AUPH icon
15
Aurinia Pharmaceuticals
AUPH
$1.92B
$32.8M 1.3%
4,808,483
– –
CMTA
16
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$31.8M 1.26%
2,707,734
+566,037
+26% +$7.04M
SYBX
17
DELISTED
Synlogic
SYBX
$29.6M 1.18%
281,961
– –
MRKR icon
18
Marker Therapeutics
MRKR
$20.2M
$27.8M 1.1%
+500,000
New +$36.4M
ARDX icon
19
Ardelyx
ARDX
$1.24B
$27.4M 1.09%
15,335,047
– –
DERM
20
DELISTED
Dermira, Inc.
DERM
$25.2M 1%
3,506,649
– –
SBBP
21
DELISTED
Strongbridge Biopharma plc.
SBBP
$18.6M 0.74%
4,141,308
– –
KA
22
DELISTED
Kineta, Inc. Common Stock
KA
$18M 0.71%
39,691
– –
AFMD
23
DELISTED
Affimed
AFMD
$16M 0.63%
513,889
– –
LXRX icon
24
Lexicon Pharmaceuticals
LXRX
$1.03B
$15.8M 0.63%
2,382,286
– –
LITS
25
Lite Strategy Inc
LITS
$33.2M
$15.1M 0.6%
286,029
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q4 2018 Portfolio in Review

As of Q4 2018, NEA Management Company held 47 positions worth $2.52B, up 8.8% from $2.32B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

NEA Management Company deployed $511M of net new capital in Q4 2018, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was Elastic: 6,353,498 shares worth $454M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 94% a quarter earlier, followed by Technology and Industrials.

On the sell side, the most notable exit was AYTU BioPharma, an estimated $6K sold.

  • NEA Management Company's largest Q4 2018 buy was Elastic: 6,353,498 shares worth $454M.
  • NEA Management Company added most to Ra Pharmaceuticals, Inc. Common Stock in Q4 2018, an estimated $10.1M increase.
  • NEA Management Company fully exited AYTU BioPharma in Q4 2018, selling an estimated $6K.
  • NEA Management Company's ten largest holdings make up 78% of its $2.52B portfolio in Q4 2018.
  • NEA Management Company opened 3 new positions and closed 1 in Q4 2018.
  • NEA Management Company's portfolio value rose 8.8% quarter-over-quarter to $2.52B.

Based on NEA Management Company's 13F filing for Q4 2018, filed 18 Jan 2019.